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METHODS: Cell lines: Adherent epithelial cell lines were used:RT-112 -Human urinary bladder transitional carcinoma cell lines, histological grade G2 (moderately differentiated). PNT2 -Normal (virally transformed) Human prostate epithelial cell line. These cells were grown using routine cell culture techniques supplemented with 10% foetal calf serum and antibiotics. Proliferation assay: The assay recorded residual viable biomass (RVB) 72 hours into exposure with the agent being studied RESULTS: Doubling dilution of morphine produced a bell-shaped curve, with high (non-clinical)concentrations inhibiting growth, followed by stimulation between 100 and 1 microgram per ml (clinically relevant concentrations shown in Figure 1 green circle), reverting to control levels thereafter. The near-normal PNT-2 cell line showed minimal responsiveness to morphine Incubation with naloxone alone has little effect on residual biomass compared to controls Conversely, pre-incubating with a fixed concentration of Naloxone, then titrating morphine across the plate showed stimulation to decrease as the relative proportion of blocker rises ( Figure 2) CONCLUSIONS: Morphine in clinically relevant concentrations stimulated growth in the RT-112 transitional carcinoma cell line, as assessed by the MTT assay. This effect was minimal under the same conditions using the virally transformed normal prostate cell line (PNT2). Treating cells with the antagonists Naloxone or Naltrexone inhibited the action of morphine. The tentative implication is that using opioids in cancer patients despite their important role in pain relief may also tend to promote tumour growth.
Source of Funding: None

MP48-12 EXTRAORDINARY ELEVATION OF SERPINB2 GENE AFTER ANTI-CANCER DRUG TREATMENT IN BLADDER CANCER
Miho Hiraki*, Naoko Arichi, Hirofumi Kishi, Haruki Anjiki, Hiroaki Yasumoto, Hiroaki Shiina, Izumo, Japan INTRODUCTION AND OBJECTIVES: The second line chemotherapy against advanced bladder cancer has not been established. We hypothesize that highly activated genes after anti-cancer drug treatment is related to the key for predicting the anti-tumor effect. For this purpose, a comprehensive analysis using cDNA microarray was performed to identify the common target genes after treatment of chemotherapeutic agent.
METHODS: Bladder cancer cell lines of T24, RT4, UMUC3, and prostate cancer cell line of PC3 were used as control. Clinical samples from 26 cases with muscle invasive bladder cancer who underwent radical cystectomy were also used. Anti-cancer drugs used were docetaxel (DTX), gemcitabine (GEM) and Cis-platinum (CDDP). The cell viability was evaluated by an MTT assay. Gene expression profiles in T24 cells were identified using cDNA microarray, which showed significant difference before and after treamnent of 1.1mM docetaxel (DTX). Individual gene expression was validated by quantitative RT-PCR. Functional study of the candidate genes was performed using specific siRNA transfection.
RESULTS: We identified SERPINB2 gene with the GO term of "negative regulation of apoptosis" as extraordinarily activated gene after DTX treatment (Z score¼7.509) . In T24 and UMUC3 cells, SERPINB2 expression was significantly increased in a stepwise manner of DTX concentration, while no significant elevation of SERPINB2 was found in RT4 cells (Table) . Likewise, CDDP extraordinarily enhanced the SER-PINB2 expression in T24 and UMUC3, but not in RT4. On other hand, GEM significantly accelerated the SERPINB2 expression in T24, while it did not in UMUC3 and RT4. UMUC3 cells, in which high SERPINB2 expression was found before treatment, showed significant reduction of cell viability after transfection of SERPINB2 siRNA, suggesting that SERPINB2 might function as oncogene. In addition, in PC3 where SERPINB2 was highly expressed before treatment, SERPINB2 knockdown by siRNA transfection showed significant reduction of cancer cell survival. In clinical samples, there was no significant difference in SERPINB2 expression between normal and cancer tissues. Interestingly, SERPINB2 expression was significantly higher in 4 cases who underwent both neoadjuvant chemotherapy (NAC) and cystectomy than in 22 cases who did cystectomy alone.
CONCLUSIONS: In certain bladder cancers, SERPINB2 might function as oncogene and is highly up-regulated. Activation of SER-PINB2, which is frequently found after anti-cancer agent treatment, might provide the essential information regarding the chemotherapeutic strategy in bladder cancer.
Source of Funding: none
MP48-13 LOSS OF FORKHEAD BOX PROTEIN O1 (FOXO1) IN BLADDER CANCER INDUCES TUMOR PROGRESSION AS WELL AS CHEMORESISTANCE
Hiroki Ide*, Tokyo, Japan; Satoshi Inoue, Taichi Mizushima, Rochester, NY; Eiji Kashiwagi, Fukuoka, Japan; Mototsugu Oya, Tokyo, Japan; Alexander Baras, Baltimore, MD; Hiroshi Miyamoto, Rochester, NY INTRODUCTION AND OBJECTIVES: Recent preclinical evidence has indicated the involvement of androgen receptor (AR) signals in bladder cancer outgrowth as well as chemosensitivity. Meanwhile, we have demonstrated that AR signals modulate the expression and activity of FOXO1, a transcriptional factor known to induce apoptosis through the PI3K-Akt pathway, in bladder cancer cells. In this study, we investigated the role of FOXO1 in bladder cancer progression as well as resistance to cisplatin treatment. Vol. 197, No. 4S, Supplement, Sunday, May 14, 2017 THE JOURNAL OF UROLOGY â e641
